» Articles » PMID: 1535178

Predictive Testing for Huntington Disease in Canada: Adverse Effects and Unexpected Results in Those Receiving a Decreased Risk

Overview
Journal Am J Med Genet
Specialty Genetics
Date 1992 Feb 15
PMID 1535178
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

By January 1, 1991, a total of 388 persons had enrolled in the Canadian collaborative study of predictive testing for Huntington disease (HD). Of these participants, 105 persons have been given a decreased risk result. Contrary to expectations, approximately 10% of persons with a decreased risk result have had psychological difficulties coping with their new status. Here, we describe the individual responses of 6 such persons and experimental themes emerging after following these persons for up to 2 years. Individuals who are more likely to suffer an adverse reaction to a decreased risk result include those persons who have made irreversible decisions based on the belief they would develop HD or those who had unrealistic overoptimistic expectations of the positive effects of a decreased risk result. In contrast to those receiving an increased risk result, the most vulnerable time for persons receiving a decreased risk result is between 2 and 12 months after learning the outcome. The need for assessment and counselling of participants in predictive testing programs, even when there is a decreased risk result, is emphasized.

Citing Articles

The Evolving Role of Diagnostic Genomics in Kidney Transplantation.

Soraru J, Chakera A, Isbel N, Mallawaarachichi A, Rogers N, Trnka P Kidney Int Rep. 2022; 7(8):1758-1771.

PMID: 35967121 PMC: 9366366. DOI: 10.1016/j.ekir.2022.05.019.


Evaluating the Effect of Kaftrio on Perspectives of Health and Wellbeing in Individuals with Cystic Fibrosis.

Aspinall S, Mackintosh K, Hill D, Cope B, McNarry M Int J Environ Res Public Health. 2022; 19(10).

PMID: 35627651 PMC: 9141876. DOI: 10.3390/ijerph19106114.


Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.

Ketchum F, Chin N, Grill J, Gleason C, Erickson C, Clark L Alzheimers Dement. 2022; 18(10):1969-1979.

PMID: 35213786 PMC: 9402800. DOI: 10.1002/alz.12620.


Causal Attributions in an Australian Aboriginal Family With Marfan Syndrome: A Qualitative Study.

McInerney-Leo A, West J, Meiser B, West M, Brown M, Duncan E Front Genet. 2020; 11:461.

PMID: 32457804 PMC: 7221064. DOI: 10.3389/fgene.2020.00461.


Neutral, Negative, or Negligible? Changes in Patient Perceptions of Disease Risk Following Receipt of a Negative Genomic Screening Result.

Stuttgen K, Pacyna J, Kullo I, Sharp R J Pers Med. 2020; 10(2).

PMID: 32316380 PMC: 7354612. DOI: 10.3390/jpm10020024.